Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
13 févr. 2024 07h00 HE
|
Eyenovia, Inc.
Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi NEW YORK, Feb. ...
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
16 janv. 2024 07h00 HE
|
Eyenovia, Inc.
MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007 Part of corporate...
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
13 nov. 2023 16h05 HE
|
Eyenovia, Inc.
Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline...
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
06 nov. 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for...
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
02 nov. 2023 07h00 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for...
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
30 oct. 2023 07h00 HE
|
Eyenovia, Inc.
Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) --...
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
09 oct. 2023 07h00 HE
|
Eyenovia, Inc.
In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions Presentation to be made at the American Academy of...
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
21 sept. 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for...
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...
Eyenovia Announces $12 Million Registered Direct Offering
24 août 2023 18h47 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for...